Last reviewed · How we verify

NCT03667313: TIS2

Treatment of In-Stent Restenosis 2 Study

Completed Phase 3 Last updated 7 December 2022
What this trial tests

Phase 3 trial testing sirolimus-eluting balloon (SEB) MagicTouch in Coronary Restenosis in 200 participants. Completed in 31 December 2021.

Timeline
1 October 2018
Primary endpoint
30 November 2021
31 December 2021

Quick facts

Lead sponsorUniversity Hospital Ostrava
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment200
Start date1 October 2018
Primary completion30 November 2021
Estimated completion31 December 2021
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Ostrava

Who can join

18 and older, any sex, with Coronary Restenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to compare the efficacy of sirolimus-eluting balloon catheters (SEB) and iopromide-coated paclutaxel-eluting balloon catheters (PEB) in the treatment of bare metal (BMS) - or drug-eluting stents restenosis (DES-ISR).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Intrastent Restenosis: A Comprehensive Review.
    Bajeu IT, Niculescu AG, Scafa-Udriște A, Andronescu E. · · 2024 · cited 18× · PMID 38338993 · DOI 10.3390/ijms25031715
  2. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
    Pleva L, Kukla P, Kovarnik T, Zapletalova J. · · 2025 · cited 4× · PMID 40171676 · DOI 10.1161/circinterventions.124.014677

Verify or expand the search:

Other recruiting trials for Coronary Restenosis

Currently open trials in the same condition.

Other University Hospital Ostrava trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03667313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing